Perimenopause: the transition, not the destination

Menopause is a single day. It is the 12-month anniversary of your final period. Everything before that, going back up to a decade, is perimenopause. This is the window when your ovaries get erratic before they eventually wind down.

Doctors and researchers use a reference framework called STRAW+10 (the international staging system for reproductive aging). It splits the window into two phases. "Early menopause transition" means your cycles start to differ by 7 or more days from one to the next. "Late menopause transition" means you skip cycles, with gaps of 60 or more days. Postmenopause begins one year after your last period and lasts the rest of your life.

For most women, perimenopause kicks off somewhere between 40 and 47. A meaningful minority hit it earlier. The SWAN cohort, the longest study to track the transition in a multi-ethnic US sample, found that frequent hot flashes lasted a median of 7.4 years. They kept going for a median of 4.5 years after the final period (SWAN, JAMA Internal Medicine 2015). So the popular image of menopause as a brief inconvenience is not what the data show. It is closer to a life chapter than a season.

Three framings to drop early. Perimenopause is not a disease. It is not a deficiency. And it is not a one-symptom syndrome. It is a normal endocrine transition, often a demanding one, and the experience varies wildly. Some women barely notice. Roughly a quarter report symptoms bad enough to interfere with work or relationships. Both are normal. Knowing where you sit in the staging matters, because the same symptom can mean different things at 43 with regular periods than at 51 after a year of skipped ones.

Perimenopause is not a hot-flush problem with a few extras. It is a whole-body transition. The symptom mix varies between women, and within the same woman over time.

Start with the most famous one. Vasomotor symptoms (hot flushes and night sweats) affect roughly 75-80% of women at some point. Severity ranges from background warmth to drenching night sweats that wreck your sleep for years. Sleep itself is its own beast. The SWAN cohort plus experimental work by Joffe and colleagues, who used a GnRH-agonist to trigger the hormonal shift, confirmed a causal link: objective hot flashes worsen objective sleep efficiency. But plenty of women also develop insomnia that has nothing to do with night sweats. Early waking. Racing-mind nights. Lighter sleep. The two problems then compound each other.

Mood and cognition deserve careful framing. Perimenopause genuinely raises the risk of new depression and anxiety, even in women with no prior history. This is biology, not weakness, and it warrants real attention rather than self-diagnosis. If mood symptoms feel out of proportion to your circumstances, or they last for weeks, talk to your GP or a Hausärztin or Frauenärztin. Do not wait.

On cognition: SWAN's long-term data (Greendale, Neurology 2009) found a measurable but reversible dip in processing speed and verbal memory during the transition. It recovers in early postmenopause. So the "brain fog" is real, and it is usually not the start of dementia.

Urogenital changes are badly under-discussed. Vaginal dryness, recurrent UTIs, urinary urgency, and discomfort during sex are all common. They often show up late in the transition, and unlike hot flushes they do not resolve on their own. Round out the picture with joint aches (the so-called "menopause joint"), heart palpitations, shifting migraine patterns, weight moving toward the midsection, and changes in skin and hair. None of these are imagined. None of them are diagnostic on their own.

The popular story is that estrogen "drops." For perimenopause, that is misleading. The defining feature of the early transition is volatility, not depletion. Estradiol can spike well above premenopausal levels in some cycles, then crash in others. FSH (follicle-stimulating hormone, the signal your brain sends to your ovaries) rises as the brain shouts louder at ovaries that respond less and less. But FSH is erratic in early perimenopause too. That is why a single blood test on a random cycle day is almost meaningless for diagnosis in your 40s. At this stage, diagnosis is clinical: based on your cycle changes and your symptoms.

Your heart and metabolism shift in ways that stack on top of normal aging. The SWAN heart study and others document faster visceral fat gain, a less friendly lipid profile (rising LDL, falling HDL), and a measurable bump in cardiovascular risk markers across the transition. Some of that happens independent of weight change.

Bone loss speeds up too. The fastest yearly rate of trabecular bone loss starts roughly one year before your final period and peaks in the two years afterward. That is one reason it pays to spot fracture risk early. The window where loading and weight-bearing exercise pay off the most is right now, not after the diagnosis.

The brain adapts as well. A 2021 multi-modality neuroimaging study (Mosconi, Scientific Reports 2021) compared pre-, peri-, and postmenopausal women. It found stage-related differences in brain structure, connectivity, and energy metabolism, with grey-matter volume and some metabolic measures looking more favourable in postmenopause than in perimenopause. The study is cross-sectional, so "recovery" is inferred from differences between groups, not tracked within the same women over time. This is a likely neurobiological correlate of brain fog. None of it means the brain is breaking. It means the brain is reorganising under different hormonal conditions.

Some interventions are well-supported by trials. Others are wishful thinking with a wellness budget. Here is the honest map.

Strength training is the single highest-payoff lifestyle move for this life stage, full stop. The LIFTMOR trial (Journal of Bone and Mineral Research, 2018) showed that high-intensity progressive resistance and impact training improved bone mineral density at the spine and femoral neck in postmenopausal women with low bone mass. That is a group previously told to avoid heavy loading. Muscle is also the largest glucose sink in your body, which directly counters the metabolic drift of the transition. The prescription: two to three structured sessions a week, with progressive loading.

Sleep hygiene becomes non-optional, but be realistic. When night sweats are the driver, behavioural sleep tweaks alone only go so far. Cooling the bedroom (16-18°C), moisture-wicking sleepwear, and a consistent wake time all help. For chronic insomnia in this group, CBT-I (cognitive behavioural therapy for insomnia, the structured talking-therapy protocol for long-term sleep problems) has the strongest evidence base. In Germany, it is reimbursable through statutory health insurance (gesetzliche Krankenkasse).

Now diet, where the evidence is messier than wellness marketing would have you believe. A Mediterranean-style way of eating is linked to better heart and metabolic outcomes broadly, midlife women included. Claims for specific "menopause diets" or phytoestrogen-heavy protocols rest mostly on observational and short-term trial data. Useful, not definitive. Adequate protein (roughly 1.2-1.6 g/kg body weight) supports muscle retention alongside strength training. And alcohol reliably worsens hot flashes and sleep for most women at this stage. Cutting back tends to pay off fast.

Stress regulation is genuinely physiological here, not just a wellness add-on. Your HPA axis (the hypothalamus-pituitary-adrenal stress system) and the sex steroid axes are tangled together, and unmanaged chronic stress amplifies symptoms. Anything with RCT evidence behind it is reasonable: mindfulness-based stress reduction, yoga, structured aerobic exercise. What does not have strong evidence: supplement stacks marketed for menopause, "cortisol detoxes," and bioidentical compounded preparations sold outside clinical channels.

This is the topic where the public conversation has done the most damage, and it is now slowly course-correcting. The headline: hormone therapy (HRT in the UK, MHT or menopausal hormone therapy in current international usage) is back in the mainstream conversation for women with symptoms. But the decision is genuinely individual, and it belongs in a consultation with your Frauenärztin, Gynäkologin, or Wahlärztin (in Austria), not on the internet. For the full protocol-level read on HRT and TRT in DACH, see our companion guide on Hormonersatztherapie & TRT.

Three references matter in 2026:

• NICE NG23 (UK, updated November 2024)
• The NAMS 2022 Hormone Therapy Position Statement
• The DGGG/OEGGG S3 Leitlinie Peri- und Postmenopause (AWMF 015-062, the 2020 version with a September 2020 addendum)

One caveat on that last one. Its AWMF validity expired at the end of 2024, the guideline has been officially under revision (in Überarbeitung) since 2025, and the updated version is expected through 2026. So when a DACH clinician quotes the S3, ask whether they mean the 2020 text or the upcoming revision. All three guidelines land on similar core principles, even where the dosing and product details differ.

Here is what current guidelines broadly agree on, in plain terms. For healthy women under 60, or within 10 years of menopause, with bothersome vasomotor symptoms, the benefit-risk profile of MHT is generally favourable. The scary harm signals from the original Women's Health Initiative (WHI) reports were partly an artefact of an older study population (mean age 63), and later re-analyses have reframed them. The 18-year follow-up of the WHI (Manson, JAMA 2017) found no significant difference in all-cause mortality between women randomised to hormone therapy and women on placebo over long-term follow-up. The ELITE trial (NEJM 2016) directly tested the "timing hypothesis." It found an effect on the progression of subclinical atherosclerosis only in women who started therapy within six years of menopause, not later. That said, ELITE's benefit was on a surrogate measure, not on actual cardiovascular events.

Breast cancer risk depends on the formulation and how long you take it. In WHI long-term follow-up (Chlebowski, JAMA 2020), the rise in breast cancer cases was concentrated in the combined oestrogen + progestin arm (CEE + MPA). The oestrogen-alone arm (CEE in women after hysterectomy) showed no comparable rise. On extended follow-up it actually showed a significant reduction in both breast cancer incidence and breast cancer mortality. So a flat "HRT raises breast cancer" summary over-simplifies.

What this does not mean. It does not mean MHT is risk-free. It does not mean every woman should be on it. And it does not mean compounded "bioidentical" preparations are safer than regulated products. They are not, and major guidelines specifically caution against unregulated compounded formulations. Your individual breast cancer risk, your cardiovascular history, your migraine pattern, the type of progestogen used, and the route of administration all matter. The point is simple. A flat "HRT is dangerous" position is not where the evidence sits in 2026, and the conversation deserves a real consultation rather than a default no.

There is no perimenopause panel that your Krankenkasse reimburses as a screening package. What gets covered depends on what is investigated and why. Here is a practical approach.

When it is clinically indicated, the gesetzliche Krankenkasse generally covers a gynaecological exam, basic blood work (TSH, ferritin, full blood count, lipids, and HbA1c when risk factors are present), and a bone density scan (DEXA, or Knochendichtemessung) when there is a fracture history or a clear osteoporosis risk. One thing to know: routine DEXA screening before age 65 in women without symptoms is usually not covered, and lands in IGeL/Selbstzahler (self-pay) territory.

Private or IGeL pricing usually applies to "menopause panels" with estradiol, FSH, LH, AMH, and progesterone, to cardiometabolic panels beyond standard lipids, and to elective DEXA for baseline tracking. Hormone testing is also genuinely cycle-day-dependent. A randomly timed estradiol in early perimenopause can read almost anything. So insist that any hormone panel comes with a specific cycle-day rationale. Without one, it is basically a vanity test. In Austria, the Wahlärztin pathway gives you longer appointments and easier access to extended panels, with partial reimbursement through the e-card system afterward.

Mental health screening matters, and it routinely gets left out. A validated questionnaire (PHQ-9 for depression, GAD-7 for anxiety) takes five minutes and is the right baseline at this life stage. If it flags anything, GKV-covered psychotherapy referral exists in Germany, though the waiting lists are long.

So what does an honest minimum baseline look like for most women entering or in perimenopause? Blood pressure, a lipid panel, HbA1c, TSH, ferritin, vitamin D (if not measured in the last two years), and at least one validated mental-health questionnaire. A baseline DEXA as an IGeL is reasonable to consider if there is a family history of osteoporosis or any fragility-fracture history. And cycle tracking (a notebook or an app) is a high-value self-knowledge tool, not a diagnostic.